https://journalsmededu.pl/index.php/OncoReview/issue/feedOncoReview2025-02-18T18:57:36+01:00Marcin Kuzmamarcin@journalsmededu.plOpen Journal Systems<p>The main area of <em>OncoReview’s </em> scientific mission is the emerging field of interdisciplinary oncology, with particular emphasis on cardio-oncology. Scientific papers published in the journal concern modern diagnostic and therapeutic methods used in this population of patients, as well as all adverse events related to anticancer treatment. Objective assessment of the benefits and risks of new oncological drugs is a unique benefit of the published works. <br><span lang="en-GB"><br></span><span lang="en-GB"><strong>e-ISSN: </strong>2450-6125 <strong> DOI: </strong>10.24292/01.OR<br><br><strong>Indexed in: </strong></span><strong>SCOPUS</strong>: SJR = 0.125; SNIP = 0.099<br><span lang="en-GB"> Polish Journals Master List: <strong>20 points</strong> <br> Index Copernicus: 116.25 <br> Google Scholar<br> Polish Medical Bibliography</span></p> <p> </p>https://journalsmededu.pl/index.php/OncoReview/article/view/3162Hormonal receptor status with relation of subtypes and association of proliferation marker Ki-67 in breast cancer patients; a potential biomarker in patients with breast cancer2025-02-18T18:57:03+01:00Vijay Pratap Singhvijaypsingh_2000@yahoo.comRahul Kumar Choudharyvijaypsingh_2000@yahoo.comArun Kumar Jhadr.arunkujha@gmail.comChandan Kumar Singhchandanksingh15@gmail.comAkash Kumar Singh Singhakashksingh84@gmail.comAvinash Pandeysaveraoncojournals@gmail.comAnita Kumarisaveraoncojournals@gmail.comVishal Mohan Singhsaveraoncojournals@gmail.comAmrita Rakesh saveraoncojournals@gmail.comAnadita Jhasaveraoncojournals@gmail.comPranab Kumar Vermavijaypsingh_2000@yahoo.comManish Jaipuriyarvijaypsingh_2000@yahoo.comShambhwi Sharmavijaypsingh_2000@yahoo.comSanjay Kumarvijaypsingh_2000@yahoo.comAjeet Kumar Singhvijaypsingh_2000@yahoo.com<p><strong>Background</strong>: Hormone receptor status is an important prognostic and therapeutic tool in breast cancer. The present study aimed to determine the comprehensive analysis of hormone receptor status and Ki-67 in breast cancer patients at a tertiary cancer centre.</p> <p><strong>Methods</strong>: The relationship of subtypes ER+PR+, ER+PR-, HER2 subtype (Luminal HER2; ER+PR+HER2+), and HER2 enriched (ER-PR-HER2+) status with multiple variables were evaluated. The expression of Ki-67 was strongly associated with cancer proliferation and is a known indicator of prognosis and outcome. The study was carried out in Savera Cancer and Multispeciality Hospital, Patna, India.</p> <p><strong>Result</strong>: This study includes a total of (n=979) breast cancer cases diagnosed at our centre, out of which (n=335; 34.22%) cases went through hormonal investigation. Luminal A (31.05%) subtype was the most prevalent, followed by triple negative (20.16%), luminal B (8.4%), and HER2-positive (20.05%). Majority of the tumours were located on right side (n=186; 55.52%), on the left (n=131; 39.1%) and bilateral (n=18; 5.37%) not significant (P <0.0003). As per ECOG performance status criteria 148 (44.17%) patients were on scale 3, 89 (26.56%) – on scale 2 and 24, 37, and 37 – on scale 0, 1 and 4 respectively statistical value (P=0.325). Remarkable finding in this study Ki-67 level was increased in >50% cases of TNBCs which was significant (P=0.05). As per AJCC staging criteria (n=205; 61.19%) cases were in stage III (locally advanced breast cancer). The value was significant (P=0.05). A total of 236 (72.39%) patients are alive with life expectancy of >24 months.</p> <p><strong>Conclusion</strong>: In conclusion, this retrospective study demonstrated a high prevalence rate of triple negative breast cancer at our centre. Majority of cases were of TNBC subtypes. Another remarkable finding of this study was, in majority of triple negative cases Ki-67 level was >50%. Elevated level of Ki-67 indicated the aggressiveness of tumor types.</p>2024-12-31T00:00:00+01:00Copyright (c) 2025 Medical Educationhttps://journalsmededu.pl/index.php/OncoReview/article/view/3198Recombinant ADAMT S-13 as a new alternative for the patients with congenital thrombocytopenic purpura2025-02-18T18:57:26+01:00Izabela Filariza.filar@gmail.comMichał Witkowskimichalwitkowski13@gmail.comWiktoria Ryżewskawiktoria.ryzewska@gmail.comTadeusz Robaktadeusz.robak@umed.lodz.pl<p>Congenital thrombocytopenic purpura (cTTP), also known as Upshaw–Schulman syndrome is a rare disease, caused by ADAMTS13 deficiency. This condition may result in various complications, including haemolytic anaemia, renal dysfunction or thrombotic events. To this very day, the most common treatment of this condition is transfusion of fresh frozen plasma.</p> <p>Recently, recombinant ADAMTS13 (rADAMTS13) has been introduced, representing a revolutionary advancement in the treatment of cTTP, and giving patients new, more comfortable alternative.</p> <p>We present here a case report of a patient with congenital thrombocytopenic purpura, who after 30 years of being treated with FFP transfusions and developing complications from both the disease and its treatment, was successfully transitioned to rADAMTS13 therapy.</p>2024-12-31T00:00:00+01:00Copyright (c) 2025 Medical Educationhttps://journalsmededu.pl/index.php/OncoReview/article/view/3189Exposure to selected environmental xenoestrogens and breast cancer – a review of recent studies2025-02-18T18:57:36+01:00Izabela Domańskaizabeladomanska@gmail.comAleksandra Sagansgn.aleksandra@gmail.comMonika Domagałamonika.domagala@interia.plWeronika Dudaweeronika.wojtowicz@gmail.comEmilia Majewskaemiliamajewska98@gmail.comMałgorzata Piśkiewiczpiskiewicz.malgorzata@gmail.comJoanna Wiewiórajoannawiewiora@onet.pl<p>Breast cancer is one of the most frequently diagnosed cancers in women worldwide and poses a significant<br>challenge to modern medicine and public health. The increase in the incidence of this type<br>of cancer is associated with various factors, including genetic, hormonal, lifestyle, and exposure to<br>harmful environmental substances. In recent years, particular attention has been paid to xenoestrogens<br>– synthetic chemical compounds present in the environment that mimic the action of natural<br>estrogens and can disrupt the human hormonal system. Xenoestrogens are found in many everyday<br>products, such as plastic packaging, cosmetics, detergents, and some pesticides. Scientists increasingly<br>indicate a possible link between their action and an increased risk of breast cancer development.<br>The mechanism of action of these substances is based on their ability to bind to estrogen receptors<br>in the body's cells, which may promote uncontrolled cell division and the development of cancerous<br>changes. This paper aims to present the mechanisms of action of selected environmental xenoestrogens,<br>their sources in the human environment, and discuss current research on their potential impact<br>on breast cancer risk.</p>2024-12-31T00:00:00+01:00Copyright (c) 2025 Medical Education